share_log

Surgery Partners Posts Weak Sales, Joins Kosmos Energy, Moderna And Other Big Stocks Moving Lower On Monday

Benzinga ·  Feb 27 00:18

U.S. stocks were slightly higher, with the Nasdaq Composite gaining around 10 points on Monday.

Shares of Surgery Partners, Inc. (NASDAQ:SGRY) fell sharply during Monday's session following weak quarterly sales.

Surgery Partners posted adjusted earnings of 44 cents per share, versus market estimates of 38 cents per share. The company's quarterly sales came in at $735.40 million missing expectations of $741.40 million, according to data from Benzinga Pro.

Surgery Partners shares tumbled 7.8% to $30.43 on Monday.

Here are some other big stocks recording losses in today's session.

  • Intuitive Machines, Inc. (NASDAQ:LUNR) dipped 25.1% to $7.18 after the company said its lunar lander may have tipped over upon landing on the moon.
  • Nyxoah S.A. (NASDAQ:NYXH) fell 11.3% to $15.29. Nyxoah is expected to release fourth quarter financial results on March 5, 2024.
  • Jin Medical International Ltd. (NASDAQ:ZJYL) fell 11.2% to $6.30.
  • TransMedics Group, Inc. (NASDAQ:TMDX) dipped 8.6% to $75.99. TransMedics Group is expected to release financial results for the fourth quarter after market close on Feb. 26, 2024.
  • World Acceptance Corporation (NASDAQ:WRLD) declined 7% to $120.71. World Acceptance recently reported better-than-expected third-quarter financial results.
  • MacroGenics, Inc. (NASDAQ:MGNX) fell 7% to $16.88.
  • Kosmos Energy Ltd. (NYSE:KOS) dipped 7% to $5.55. Kosmos Energy reported a fourth-quarter fiscal 2023 revenue decline of 10% year-over-year to $507.81 million, beating the consensus of $477.73 million.
  • Orla Mining Ltd. (NASDAQ:ORLA) fell 6.8% to $3.38.
  • Insulet Corporation (NASDAQ:PODD) fell 5.8% to $173.54 after Barclays maintained an Equal-Weight rating on the stock and lowered its price target from $214 to $213.
  • Summit Therapeutics Inc. (NASDAQ:SMMT) declined 5.6% to $4.38.
  • Moderna, Inc. (NASDAQ:MRNA) fell 4.3% to $92.36 after HSBC downgraded the stock from Hold to Reduce but raised its price target from $75 to $86.

Now Read This: Top 3 Defensive Stocks That May Collapse In February

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment